surmount-1 trial tirzepatide non-diabetic obesity weight loss for the Maintenance of Body Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - SURMOUNT-1: In an RCT, adults
Description
Some people find tirzepatide easier to tolerate, while others have a smoother experience on semaglutide a variability driven by factors like genetics, diet, and individual dose escalation protocols
Blood glucose monitoring is essential, particularly for patients on insulin or sulfonylureas, during tirzepatide initiation and dose escalation
the FDA does not evaluate compounded medications for safety or efficacy
When this happens, patients sometimes receive vials with different concentrations than their previous shipment
The total calories may be the same as three larger meals, but the distribution across the day matches your altered digestive capacity much better
[5] [6] However, weight loss was consistently reported as an adverse event in the original studies, especially in overweight or obese patients
